Faber Logo
Skip to main content

Recent Transactions

Our latest work in the life sciences and high-tech fields.

Our work

Tasca Therapeutics Corp. Logo

Tasca Therapeutics Corp.

Series A Financing

Tasca Therapeutics launches with $52 million in Series A financing co-led by Regeneron Ventures and Cure Ventures, and with participation by Invus Group.

Press Release
GV (Google Ventures) Logo

GV (Google Ventures) + PeopleOne Health

Series B Financing

Representation of GV Management Company as lead in PeopleOne Health’s $32.3M Series B Financing.

Press Releasse
EvolveImmune Therapeutics, Inc. Logo

EvolveImmune Therapeutics, Inc. + AbbVie

Collaboration and License Agreement

EvolveImmune Therapeutics in a collaboration and option-to-license agreement with AbbVie to develop multispecific biologics for multiple targets in oncology leveraging EvolveImmune’s T-cell engager platform, with an upfront payment of $65 million, up to $1.4 billion in option fees and milestones, as well as tiered royalty payments on net sales

Press Release
Ananda Scientific, Inc. Logo

Ananda Scientific, Inc.

Investigator Initiated Clinical Trial

Counsel to Ananda Scientific in collaboration with Yale School of Medicine to conduct investigator initiated clinical trial evaluating Nantheia™ ATL5 for use in treating co-occurring opioid use disorder (OUD) and chronic pain. The study will be led by Principal Investigator Joao P. De Aquino, M.D.

Press Release
Novo Nordisk A/S Logo

Novo Nordisk A/S + 2seventy bio

Asset Purchase Agreement & Grant-Back License Agreement

Counsel to Novo Nordisk in acquisition of 2seventy’s Hemophilia A program and rights to MegaTAL in vivo gene editing technology.

Press Release
GV (Google Ventures) Logo
GV (Google Ventures) Logo

GV (Google Ventures) + a16z Bio + Health + Santa Ana Bio, Inc

Series B Financing

Representation of GV Management Company, as lead, and a16z Bio + in Santa Ana Bio’s $125M Series B Financing. Other investors included TPG, Access Biotechnology, and RTW.

Press Release
NextPoint Therapeutics, Inc. Logo

NextPoint Therapeutics, Inc.

Series B Financing & Extension

NextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint subsequently raises $42.5M in an extension to its Series B led by Catalio Capital Management, bringing the total raised to $122.5M. Additional investors in the round include MPM BioImpact, Invus, Sixty Degree Capital, Binney Street Capital, and Arkin Bio-Capital.

Website

TMS Co., Ltd. + JiXing Pharmaceuticals + RTW Investments, LP

Strategic Collaboration Agreements

The firm counseled TMS Co. Ltd. as it entered strategic collaboration agreements with JIXING Pharmaceuticals, subsequent to the assignment of TMS-007 global rights from Biogen to JIXING. TMS regained Japan rights to this compound, received a payment of JIXING equity, and obtained Japan rights to JX09. TMS contemporaneously received a private equity investment from RTW

Press Release
Claris Biotherapeutics, Inc. Logo

Claris Biotherapeutics, Inc.

Series A-3 Preferred Stock Financing

Claris Bio closes latest venture round to bring total financing to roughly $60 million, accelerating its late-stage clinical development of a novel therapeutic agent for neurotrophic keratopathy. Investors include Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors

Press Release
GV (Google Ventures) Logo
GV (Google Ventures) Logo

GV (Google Ventures) + ARCH Ventures

Chroma Medicine Series B Financing

Representation of GV, as lead, ARCH Venture Partners and DCVC in Chroma Medicine’s $135M Series B Financing

Press Release
Paragon Therapeutics, Inc. Logo

Paragon Therapeutics, Inc. + Apogee Therapeutics, Inc.

Antibody Discovery and Option Agreement

Option for exclusive development and commercial rights to a suite of Paragon’s top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions

Press Release
6 Dimensions Capital Logo

6 Dimensions Capital

VC Investments

Equity investments in multiple portfolio companies, including Hibercell

Website
Puma Biotechnology, Inc. Logo

Puma Biotechnology, Inc.

Clinical Trial

CRO and Site Agreements for an Open-Label, Phase 2 Study with 30 Sites in 9 Countries exploring the efficiency of Neratinib on Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations Or EGFR Gene Amplification

See Study
Epalex Corporation Logo

Epalex Corporation

Series A-3 Financing

Series A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs

Website
Praeventix, Inc. Logo

Praeventix, Inc.

Private Investment

Private Investment from Tellus BioVentures

Website
Vertex Pharmaceuticals Incorporated Logo

Vertex Pharmaceuticals Incorporated

Acquisition of Private Company

Co-counsel to Vertex on acquisition of ViaCyte, a privately-held biotechnology company that received substantial research funding from the California Institute of Regenerative Medicine

Press Release
page 1 / 6

Here’s how we can help you

This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.